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Abstract
Purpose: Prostate cancer is the leading form of cancer diagnosed among North American men.
Most patients present with localized disease, which can be effectively treated with a variety of
different modalities. These are associated with widely different acute and late effects, which can be
both physical and psychological in nature. HRQoL concerns are therefore important for these
patients for selecting between the different treatment options.
Materials and methods: One year after receiving radiotherapy for localised prostate cancer 117
patients with localized prostate cancer were invited to participate in a quality of life (QoL) self
reported survey. 111 patients consented and participated in the survey, one year after completion
of their treatment. 88 patients received EBRT and 23 received EBRT and HDRBT. QoL was
compared in the two groups by using a modified version of Functional Assessment of Cancer
Therapy-Prostate (FACT-P) survey instrument.
Results: One year after completion of treatment, there was no significant difference in overall QoL
scores between the two groups of patients. For each component of the modified FACT-P survey,
i.e. physical, social/family, emotional, and functional well-being; there were no statistically significant
differences in the mean scores between the two groups.
Conclusion: In prostate cancer patients treated with EBRT alone versus combined EBRT and
HDRBT, there was no significant difference in the QoL scores at one year post-treatment.
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Background
Prostate cancer is the leading form of cancer diagnosed
among Canadian men and accounts for approximately
27% of new cancer cases and 11.4% of cancer deaths
[1,2]. Most newly diagnosed patients with prostate cancer
present with localized disease [3]. EBRT is a treatment
option for patients with early-stage or locally advanced
prostate cancer [4]. Recent data suggest that local control
of prostate cancer is directly related to the radiation dose
which would in turn result in improved biochemical con-
trol, disease-free survival and increased overall survival
[5]. Various dose escalation methods are available includ-
ing three-dimensional conformal radiotherapy (3D-CRT)
or intensity-modulated radiotherapy (IMRT) with or with-
out low-dose rate (LDR), high-dose rate (HDR) or particle
beam boost [6-9].
Health related quality of life (HRQoL) is a subjective
measure of a patient's perception of well-being. HRQoL
concerns are important for patients with prostate cancer
for selecting between different treatments options which
may result in physical and psychological sequelae that
would affect their daily lives. Evaluation of the quality of
life (QoL) among cancer patients who had received radia-
tion using different radiotherapeutic techniques certainly
helps both patients and physicians to make a more
informed decision on their treatment.
The main objective of this study was to compare prospec-
tively HRQoL at one year after treatment in prostate can-
cer patients treated with either EBRT alone or a
combination of EBRT and iridium HDRBT.
Patients and methods
Patient characteristics
This is a prospective study carried out among patients
with localized prostate cancer during the period January
2000 to December 2002, in the department of Radiation
Oncology at the Allan Blair Cancer Center (ABCC), in
Regina, Canada. One of the standard treatment options
for these patients during this period was EBRT alone. We
started the prostate HDRBT program at the ABCC in 1999.
Since then, HDRBT was used as an alternative method of
dose escalation in patients with locally advanced prostate
cancer who have received EBRT.
Patients in our study (Table 1) belonged to the intermedi-
ate or high risk groups with the following features: histo-
logical diagnosis of adenocarcinomas of the prostate,
pretreatment PSA ≤ 20 ng/ml (mean), clinical stage T1c -
T3a, prostate volume ≤ 60 cc, no evidence of lymphaden-
opathy on the pelvic CT scan, and a negative bone scan.
During the above time period, 117 patients met the above
criteria were treated at our institution with either EBRT
alone or a combination of EBRT plus HDRBT.
Radiotherapy details
All the patients who received EBRT were treated by using
3D-CRT with a 4-field box technique using 10-MV or
higher-energy photons. The EBRT alone group received a
total dose of 66–70 Gy in 33 – 35 fractions (2-Gy per frac-
tion) over six and half to seven weeks. This was the stand-
ard EBRT dose during that period (although considered to
be low compared to current standards). EBRT was deliv-
ered in two phases. The planning target volume (PTV) for
the initial phase included the prostate gland and seminal
vesicles with a margin of 1–2 cm receiving a dose of 40 Gy
in 20 fractions (2-Gy per fraction) over four weeks. The
Table 1: Characteristic of the study population
EBRT group RBRT+HDRB group
No of patients 88 23









Pretreatment PSA (ng/ml) Mean: 14.1 Mean: 12.3
Median: 8.7 Median: 8.9
Range: 1.7 – 161.8 Range: 0.8 – 51.9
≤ 10 46 14
10–20 31 5
≥ 20 11 4
Radiotherapy dose 66–70 Gy/33–35 Fr 40 Gy+16.5 Gy BrachyRadiation Oncology 2008, 3:20 http://www.ro-journal.com/content/3/1/20
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boost phase PTV for EBRT only group was defined as the
prostate with a margin of 0.7–1 cm and received a dose of
26–30 Gy in 13–15 fractions (2-Gy per fraction) over two
and half to three weeks at the discretion of the treating
Radiation Oncologist. None of the patients received
regional nodal radiation. Patients who were in the EBRT
plus HDRBT treatment group received HDRBT initially
followed by EBRT. Iridium-192 HDRBT was performed
via a transperineal approach, delivering a total dose of
16.5 Gy in 3 fractions within 24 hours with a minimum
gap of six hours between fractions. PTV for the brachyther-
apy treatment consists of the entire prostate gland and
capsule with a margin of 2–3 mm. EBRT was given two
weeks after HDRBT delivering a dose of 40 Gy at 2 Gy per
fraction over 4 weeks.
Quality of life questionnaire
All one hundred and seventeen patients who underwent
either EBRT alone or a combination of EBRT plus HDRBT
were invited to participate in an institutional review board
approved self-reported QoL survey at one year after com-
pletion of their radiation treatment. One hundred and
eleven patients consented and participated in the survey.
Eighty-eight patients of 111 received EBRT alone and 23
patients received combined EBRT and HDRBT. The survey
was conducted using a modified version of the Functional
Assessment of Cancer Therapy-Prostate (FACT-P) survey
instrument (version 3). Results between the two treat-
ment groups were compared using a paired t-test.
Results
Characteristics of the study population, according to treat-
ment received, are shown in Table 1. Median age was
identical between patients treated with EBRT alone and
those treated with EBRT and HDRB. Approximately 2/3 of
patients in both groups had stage T2 disease. There were
no significant differences between the two groups with
respect to the distribution of established risk factors
(stage, Gleason score and PSA).
Table 2 shows modified FACT-P scores at one year for the
two different treatment groups. There was no significant
difference in overall QoL between the two groups (p =
0.668). For each component of the modified FACT-P sur-
vey, i.e. Physical Well-Being, Social/Family Well-Being,
Emotional Well-Being, and Functional Well-Being, there
was no statistically significant difference in the mean
scores between the two groups.
Discussion
Patients with prostate cancer can live for many years
regardless of the treatment they receive due to the long
natural history. As a result, HRQoL has become an impor-
tant outcome measure in patients with this disease. Differ-
ent survey instruments are designed to assess HRQoL of
patients with prostate cancer [3,10,11]. We have con-
ducted our survey by using a modified version of FACT-P
(version 3) survey tool [12,13] The structure of FACT-P
(version 3) survey instrument comprising a 47-item ques-
tionnaire, which is divided into four primary QoL
domains: physical, social/family, emotional, and func-
tional well-being, plus a 12-item prostate cancer subscale.
These 12-items ask about symptoms and problems spe-
cific to prostate cancer. Higher total scores for the FACT-P
scale indicate a better overall QoL. The modified survey
instrument has a total of 50 questions and the only mod-
ification is in the prostate subscale for the purpose of
accommodating symptoms related to radiation induced
late toxicity (Table 3).
Sathya  et al reported a randomized study in which
patients with locally advanced prostate cancer were
treated with EBRT alone or combination of EBRT and irid-
ium HDRBT. The study showed no difference in the toxic-
ity scores between the two arms at 18 months of follow up
[9]. This study also provided evidence that higher doses of
radiation delivered by the combination treatment resulted
in better local as well as biochemical control in locally
advanced prostate cancer. Other studies have also
reported improved local control following dose escalation
with 3D-CRT or IMRT [7,8]. The risks of long-term mor-
bidity, following dose escalation by various methods are
incompletely understood yet and they could have a signif-
icant impact on post treatment QoL.
Various studies have demonstrated the significance of
HRQoL assessment when considering different treatment
options for prostate cancer and suggested that recom-
mended treatment decisions should take into account
HRQoL in addition to survival [12,13]. Wei et al reported
a comparative HRQoL outcome study for patients with
localized prostate cancer who underwent brachytherapy,
radical prostatectomy or EBRT [14]. Higher FACT-P scores
were reported in patients treated with EBRT than with
brachytherapy. The authors concluded that the HRQoL
changes are likely to be treatment-specific. Welsh et al
compared the baseline to six months post treatment QoL
Table 2: Comparison of Modified FACT-P scores of two 
treatment groups.
HRQoL Component: Mean score p-value
EBRT + HDRBT EBRT
Physical Well -Being 6.86 6.59 0.865
Social/Family Well-Being: 19.26 17.96 0.289
Emotional Well-Being: 9.76 9.99 0.865
Functional Well-Being: 28.78 27.13 0.252
Prostate cancer subscale: 16.86 18.38 0.447
Overall: 97.64 95.04 0.668Radiation Oncology 2008, 3:20 http://www.ro-journal.com/content/3/1/20
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of 10 patients with prostate cancer treated with EBRT plus
HDRBT [15]. They found that the median QoL scores were
comparable to baseline values at six months and con-
cluded that EBRT plus HDRBT is an acceptable treatment
when QoL is considered.
Our study compared HRQoL among patients with local-
ized prostate cancer who had undergone radical treatment
using the two different radiation techniques. Our findings
indicated that both groups had similar QoL outcomes at
the end of one year of treatment. Vordermark D et al
reported the results of a similar study among 84 prostate
cancer patients treated with either EBRT alone or EBRT
plus HDRBT [16]. The study showed comparable QoL
data between the two groups at a median duration of 19
months post treatment. HRQoL differences may not
become apparent at the end of one to two years of com-
pletion of treatment and hence a longer follow up might
be helpful to see the difference. Wahlgren T et al reported
the five year disease-specific HRQoL of patients with
localized prostate cancer following combined treatment
including EBRT, HDRBT and hormone therapy [17]. The
long term data reported that only minor differences in
general HRQoL compared with normative data. We are in
the process of reviewing HRQoL of our patients at five
years post treatment.
Our data may have significant implications. While offer-
ing curative radiation treatment, most of the patients are
interested to know how the different treatments compare
to one another in terms of survival, long term morbidity
and HRQoL. Our study showed the significance of the
evaluation of QoL which would help both patients and
physicians to make more informed decisions between dif-
ferent treatment techniques.
A potential limitation of our study is that this is a single-
institutional non-randomised study with a small sample
size in the EBRT plus HDRBT arm. In addition the study
lacks baseline HRQoL information. Radiation doses are
also low by today's standards. However the study does
help to minimise concerns of using combination treat-
ment as an alternative for dose escalation when QoL is
considered.
Conclusion
Our study showed that the impact of prostate cancer treat-
ments such as EBRT alone vs. combination of EBRT and
HDRBT on HRQoL was comparable at one year after com-
Table 3: Modified FACT-P Prostate subscale (version3). Questions 47–49 added to the FACT-P Prostate subscale (version3)
Additional Concern Not at all A little bit Some- what Quite a bit Very much
35. I am losing weight....................................... 0 1 2 3 4
36. I have a good appetite................................... 0 1 2 3 4
37. I have aches and pains that bother me 0 1 2 3 4
38. I have certain areas of my body where I 
experience significant pain
01 2 3 4
39. My pain keeps me from doing things I 
want to do...
01 2 3 4
40. I am satisfied with my present comfort 
level..........
01 2 3 4
41. I am able to feel like a 
man..............................
01 2 3 4
42. I have trouble moving my 
bowels.....................
01 2 3 4
43. I have difficulty 
urinating.......................................
01 2 3 4
44. I urinate more frequently than 
usual...................
01 2 3 4
44. I have difficulty starting to 
urinate......................
01 2 3 4
45. My problems with urinating limit my 
activities......
01 2 3 4
46 I am able to have and keep an erection 0 1 2 3 4
47. I have rectal bleeding.................................... 0 1 2 3 4
48. I have diarrhea............................................. 0 1 2 3 4
49. I have blood in my 
urine.................................
01 2 3 4
50. Looking at the above 15 questions, how much would you say these ADDITIONAL CONCERNS affect your quality of life? (circle one number)
01 2 3 4 5 6 7 8 9 1 0
Not at all Very much soPublish with BioMed Central    and   every 
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pletion of treatment. Prospective randomized studies are
needed to confirm these findings. In addition, an under-
standing of the relative HRQoL would help clinicians and
patients to make informed choices between different
treatment options that may offer a similar chance of
tumor control.
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